China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.
Deallus’ Chinese pharmaceutical market access model revolves around the following five aspects: company’s vision and objectives, drug discovery innovation, registration for approval, National Reimbursement Drug List (NRDL), Volume-based procurement (VBP) and pricing, Hospital Drug Listing (HDL) and physician perception building.
Download to read more.
You may also be interested in…
World Kidney Cancer Day: The future of RCC treatment
World Kidney Cancer Day brings much needed attention to a disease affecting hundreds of thousands of people worldwide.
Revolutionizing Blood Cancer Treatment: A Dive into Cutting-Edge Therapies
World Blood Cancer Day [28 May 2024] serves as a stark reminder of the significant challenges faced by the millions battling these life-threatening diseases. Here at Deallus, we have been privileged enough to partner with many leading companies in this space to support the development of lifechanging therapies across haemato-oncology.
World Day for Cultural Diversity 2024
Feel the driving force of Cultural Diversity as voiced by my global Deallus colleagues. Happy World Day of Cultural Diversity!
The need for innovation in Women’s Health
Women’s Health Week (14-20 May 2024) provides an opportunity to reflect on the changing landscape for the access, treatment, and representation of women across healthcare. We’re proud that many of the clients we are partnering with are part of driving much needed change and reform within Women’s Health, lending our experience and expertise to the innovation that is required.